Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23589671 | 0.90 | NAMPT (0.39) | KMT2AMEN1CASP2EPHX1NAMPT | |
| SCHEMBL23589692 | 0.90 | NAMPT (0.39) | KMT2AMEN1CASP2EPHX1NAMPT | |
| SCHEMBL22872802 | 0.90 | NAMPT (0.39) | KMT2AMEN1CASP2EPHX1NAMPT | |
| SCHEMBL23589907 | 0.90 | NAMPT (0.39) | KMT2AMEN1CASP2EPHX1NAMPT | |
| SCHEMBL23589714 | 0.90 | NAMPT (0.39) | KMT2AMEN1CASP2EPHX1NAMPT | |
| SCHEMBL23589715 | 0.90 | NAMPT (0.39) | KMT2AMEN1CASP2EPHX1NAMPT | |
| SCHEMBL22301097 | 0.88 | KMT2A (0.39) | KMT2AMEN1CASP2EPHX1NAMPT | |
| SCHEMBL21227614 | 0.85 | CASP2 (0.51) | KMT2AMEN1CASP2EPHX1NAAA | |
| SCHEMBL25101472 | 0.85 | CASP2 (0.51) | KMT2AMEN1CASP2EPHX1NAAA | |
| SCHEMBL22318122 | 0.83 | CASP2 (0.49) | KMT2AMEN1CASP2EPHX1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | FOGHORN THERAPEUTICS INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | FOGHORN THERAPEUTICS INC. | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773085-B2 | Methods and compounds for treating disorders | VHL, TFEB, BECN1 | KMT2A 583/4885MEN1 823/4885CASP2 1477/4885 |
| US-20210009568-A1 | METHODS AND COMPOUNDS FOR TREATING DISORDERS | VHL, TFEB, BECN1 | KMT2A 583/4885MEN1 823/4885CASP2 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.